Manufacturers Unable to Make Minor Changes to Products in China
This article was originally published in The Gold Sheet
Executive Summary
A lack of a reporting mechanism for minor or moderate changes to approved pharmaceuticals in China makes it difficult for pharmaceutical manufacturers to make lifecycle improvements to products marketed there. Long review timelines and unclear expectations during inspections further complicate the picture.
You may also be interested in...
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.